Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
This is written in the approval document as:
Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Citation
Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib |